These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38265075)

  • 1. Evaluating Treatment Response in GEJ Adenocarcinoma: The Role of Pretherapeutic and Posttherapeutic Iodine Mapping.
    Graf M; Gawlitza J; Makowski M; Meurer F; Huber T; Ziegelmayer S
    Invest Radiol; 2024 Aug; 59(8):583-588. PubMed ID: 38265075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computed tomography (CT) perfusion as an early predictive marker for treatment response to neoadjuvant chemotherapy in gastroesophageal junction cancer and gastric cancer--a prospective study.
    Lundsgaard Hansen M; Fallentin E; Lauridsen C; Law I; Federspiel B; Bæksgaard L; Svendsen LB; Nielsen MB
    PLoS One; 2014; 9(5):e97605. PubMed ID: 24845062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spectral CT vs. diffusion-weighted imaging for the quantitative prediction of pathologic response to neoadjuvant chemotherapy in locally advanced gastric cancer.
    Li J; Xu S; Wang Y; Ma F; Chen X; Qu J
    Eur Radiol; 2024 Sep; 34(9):6193-6204. PubMed ID: 38345605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenocarcinoma of the gastro-esophageal junction: CT for monitoring during neoadjuvant chemotherapy.
    Helmberger H; Baum U; Dittler HJ; Sendler A; Schulte B; Herter B; Fink U; Gerhardt P
    Eur J Radiol; 1996 Sep; 23(2):107-10. PubMed ID: 8886719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of repeat staging laparoscopy in locoregionally advanced gastric or gastroesophageal cancer after neoadjuvant therapy.
    Cardona K; Zhou Q; Gönen M; Shah MA; Strong VE; Brennan MF; Coit DG
    Ann Surg Oncol; 2013 Feb; 20(2):548-54. PubMed ID: 22941159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation.
    Blank S; Lordick F; Bader F; Burian M; Dobritz M; Grenacher L; Becker K; Weichert W; Langer R; Sisic L; Stange A; Jäger D; Büchler M; Bruckner T; Siewert J; Ott K
    Gastric Cancer; 2015 Apr; 18(2):314-25. PubMed ID: 24722800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis.
    Parry K; van Rossum PS; Haj Mohammad N; Ruurda JP; van Hillegersberg R
    Eur J Surg Oncol; 2017 Jan; 43(1):226-233. PubMed ID: 27424786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
    Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
    World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staging of adenocarcinoma of the gastroesophageal junction.
    Parry K; Haverkamp L; Bruijnen RC; Siersema PD; Offerhaus GJ; Ruurda JP; van Hillegersberg R
    Eur J Surg Oncol; 2016 Mar; 42(3):400-6. PubMed ID: 26777127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
    Lorenzen S; von Gall C; Stange A; Haag GM; Weitz J; Haberkorn U; Lordick F; Weichert W; Abel U; Debus J; Jäger D; Münter MW
    BMC Cancer; 2011 Jun; 11():266. PubMed ID: 21702914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy.
    Ang J; Hu L; Huang PT; Wu JX; Huang LN; Cao CH; Zheng YX; Chen L
    World J Gastroenterol; 2012 Dec; 18(47):7026-32. PubMed ID: 23323004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
    Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J
    J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [
    Harustiak T; Zemanova M; Fencl P; Hornofova L; Pazdro A; Snajdauf M; Salkova E; Lischke R; Stolz A
    Br J Surg; 2018 Mar; 105(4):419-428. PubMed ID: 29417984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative EOX treatment in operable locally advanced gastroesophageal adenocarcinoma: Prediction of tumor response by FDG -PET and histopathology.
    Vihervaara H; Ålgars A; Kemppainen J; Sundström J; Ristamäki R; Salminen P
    Surg Oncol; 2019 Mar; 28():42-49. PubMed ID: 30851910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
    Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD
    BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
    Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
    J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
    van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
    Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy.
    Beer AJ; Wieder HA; Lordick F; Ott K; Fischer M; Becker K; Stollfuss J; Rummeny EJ
    Radiology; 2006 May; 239(2):472-80. PubMed ID: 16543584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
    Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study.
    Li N; Li Z; Fu Q; Zhang B; Zhang J; Wan XB; Lu CM; Wang JB; Deng WY; Ma YJ; Bie LY; Wang MY; Li J; Xia QX; Wei C; Luo SX
    Int J Surg; 2024 Apr; 110(4):2071-2084. PubMed ID: 38320099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.